Related Experiment Video
Updated: May 30, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
Annice Mukherjee1,2, Susan R Davis3,4
1Centre for Intelligent Healthcare, Coventry University, Priory St, Coventry, CV1 5FB, UK.
Menopause hormone therapy (MHT) offers symptom relief and potential skeletal benefits for many women. Tailored MHT use, based on individual needs and shared decision-making, is recommended, acknowledging data gaps in diverse populations.
Area of Science:
- Reproductive Endocrinology
- Women's Health
- Evidence Synthesis
Background:
- Menopause hormone therapy (MHT) is a key management option for menopausal symptoms.
- Understanding the current evidence base for MHT's efficacy and safety is crucial for clinical practice.
Purpose of the Study:
- To summarize current evidence on menopause hormone therapy (MHT) for clinicians.
- To evaluate MHT's indications, efficacy, and safety, highlighting data limitations.
Main Methods:
- Systematic review and synthesis of pooled evidence from observational studies, RCTs, meta-analyses, and reviews.
- Focus on MHT outcomes in women with natural menopause, scrutinizing available data and identifying gaps.
Main Results:
- MHT impact varies significantly across demographics.
- Evidence supports MHT for symptom relief and potential midlife skeletal health benefits.
- Current data reveal menopause health inequalities and research gaps, particularly for underrepresented groups.
Conclusions:
- Tailored MHT use for specific indications is recommended, balancing benefits and risks through shared decision-making.
- MHT can provide symptom relief and skeletal benefits for many women.
- Further research is needed to address evidence gaps in diverse contemporary MHT user cohorts.
More Related Videos
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Internal Receptors
Hormonal Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

